Pulmatrix Overview
- Founded
- 2003
- Status
- Public
- Employees
- 22
- Stock Symbol
- PULM
- Investments
- 1
- Share Price
- $6.33
- (As of Monday Closing)
Pulmatrix General Information
Description
Pulmatrix Inc is a clinical-stage biotechnology company. The company is focused on the discovery and development of novel inhaled therapeutic products intended to prevent and treat respiratory diseases and infections with significant unmet medical needs. Pulmatrix designs and develops inhaled therapeutic products based on its proprietary dry powder delivery technology, iSPERSE (inhaled Small Particles Easily Respirable and Emitted), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The iSPERSE powders are engineered to be small, dense particles with dispersibility and delivery to airways.
Contact Information
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Stock Exchange
NAS
Primary Office
- 99 Hayden Avenue
- Suite 390
- Lexington, MA 02421
- United States
+1 (781) 000-0000
Pulmatrix Timeline
Pulmatrix Stock Performance
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $6.33 | $5.94 | $5.64 - $31.80 | $19.6M | 3.3M | 69.5K | -$7.00 |
Pulmatrix Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 | FY 2018 31-Dec-2018 |
|---|---|---|---|---|
| EV | (10,725) | 8,332 | (10,684) | 8,037 |
| Revenue | 6,713 | 12,634 | 7,910 | 153 |
| EBITDA | (17,894) | (18,347) | (20,132) | (20,173) |
| Net Income | (19,039) | (19,308) | (20,596) | (20,563) |
| Total Assets | 55,748 | 38,169 | 36,098 | 14,723 |
| Total Debt | 898 | 1,743 | 675 | 0 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Pulmatrix Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
This information is available in the PitchBook Platform. To explore Pulmatrix‘s full profile, request access.
Request a free trialPulmatrix Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
This information is available in the PitchBook Platform. To explore Pulmatrix‘s full profile, request access.
Request a free trialPulmatrix Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Pulmatrix Inc is a clinical-stage biotechnology company. The company is focused on the discovery and development of nove
Biotechnology
Lexington, MA
22
As of 2020
00000
00000000
00000
000000 0
olore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui of
000000000000000
San Diego, CA
000
As of 0000
00000
000000&0
0000000
magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex
0000000000000
Morristown, NJ
000
As of 0000
00000
0000
0000-00-00
000000000000
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialPulmatrix Competitors (33)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| ACADIA Pharmaceuticals | Formerly VC-backed | San Diego, CA | 000 | 00000 | 000000&0 | |
| 0000000 0000000000 | Private Equity-Backed | Morristown, NJ | 000 | 00000 | 000000000000 | |
| 00000000 000000000 | Corporate Backed or Acquired | Warrington, PA | 00 | 00000 | 00000000 | 00000 |
| 00000000 | Formerly VC-backed | South San Francisco, CA | 00 | 00000 | 0000000000. | |
| 00000000 000000000 | Corporation | Durham, NC | 000 | 00000 | 000000000 | 00000 |
Pulmatrix Patents
Pulmatrix Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2021522161-A | Antifungal formulation for intrapulmonary administration containing itraconazole | Pending | 18-Apr-2018 | 0000000000 | |
| US-20210145739-A1 | Antifungal formulations for pulmonary administration comprising itraconazole | Pending | 18-Apr-2018 | 0000000000 | |
| EP-3781125-A1 | Antifungal formulations for pulmonary administration comprising itraconazole | Pending | 18-Apr-2018 | 0000000000 | |
| US-20190167579-A1 | Itraconazole dry powders | Abandoned | 27-Oct-2017 | 0000000000 | 0 |
| CA-3039485-A1 | Antifungal dry powders | Pending | 14-Oct-2016 | A61K9/0075 |
Pulmatrix Executive Team (15)
Pulmatrix Board Members (19)
| Name | Representing | Role | Since |
|---|---|---|---|
| Anand Varadan | Pulmatrix | Board Member | 000 0000 |
| Christopher Cabell MD | Pulmatrix | Board Member | 000 0000 |
| Michael Higgins | Self | Chairman & Board Member | 000 0000 |
| Richard Batycky Ph.D | Pulmatrix | Board Member | 000 0000 |
| Steven Gillis Ph.D | Self | Board Member | 000 0000 |
Pulmatrix Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialPulmatrix Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
This information is available in the PitchBook Platform. To explore Pulmatrix‘s full profile, request access.
Request a free trialPulmatrix Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000000 | 15-Jun-2015 | 0000000000 | 000.00 | Drug Delivery |